Drug Trial Radar · NCT07781293
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
364
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Bukwang PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who show an inadequate response to antidepressant monotherapy. Eligible participants will continue their background antidepressant treatment and be randomized to receive either lurasidone (20, 40, or 60 mg/day) or placebo for 8 weeks. The primary endpoint is the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 8. Secondary endpoints include response and remission rates, changes in Clinical Global Impression-Severity (CGI-S), 17-item Hamilton Depression Rating Scale (HAM-D17), Hamilton Anxiety Rating Scale (HAM-A), and Sheehan Disability Scale (SDS) scores. Safety assessments will include adverse events, laboratory tests, electrocardiograms (ECGs), vital signs, and suicidality monitoring Columbia-Suicide Severity Rating Scale (C-SSRS).
Conditions
- Major Depressive Disorder (MDD)
- Major Depressive Disorder With Psychotic Features
Interventions
LurasidoneDrug
Lurasidone
PlaceboDrug
Placebo
Background Antidepressant TherapyDrug
Background Antidepressant treatment (ADT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Montgomery-Åsberg Depression Rating Scale Total Score at Week 8Time frame: Baseline to Week 8
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.